Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Item
http://www.wikidata.org/entity/Q35032508
Environmental endocrine disruptors: Effects on the human male reproductive systemMutation of the androgen receptor causes oncogenic transformation of the prostateSuppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.Androgen receptor drives cellular senescence.Landmarks in hormonal therapy for prostate cancer.Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancerThe expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virusLyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
P2860

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Item
http://www.wikidata.org/entity/Q35032508
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
@ast
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
@en
type
label
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
@ast
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
@en
prefLabel
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
@ast
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
@en
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
@en
P2093
P2888
P304
P31
P356
P433
P478
P577
P5875
P698